Prescription pharmaceuticals market forecast to 2022 by scalar market research

1

Global Prescription Pharmaceuticals Market, By TherapeuticSegment (Cardiovascular Disorders, Inflammatory Conditions,Metabolic Disorders, Oncology, Respiratory Disorders,Others), By Formulations (Capsules, Inhalants, Parenterals,Tablets, Topicals), By Region (Asia, Europe, North Americaand Rest of the World (RoW) – Market Size and Forecast(2013–2020)

Scalar Market Research.

June 2016

2

Table of Contents

Market Overview ..................................................................................................................................16

1.1 Definitions.............................................................................................................................16

1.2 Research Methodology .........................................................................................................16

1.3 Market Segmentation ...........................................................................................................17

1 Executive Summary.......................................................................................................................19

1.1 Global Prescription Pharmaceuticals Market .......................................................................19

1.2 Global Prescription Pharmaceuticals Market Size (US$ Billion), By Therapeutic Segments(2015 vs. 2020)..................................................................................................................................20

1.3 Global Prescription Pharmaceuticals Market Size (US$ Billion), By Formulations (2015 vs.2020) 21

1.4 Global Prescription Pharmaceuticals Market Size (US$ Billion), By Regions (2015 vs. 2020)21

2 Market Overview ..........................................................................................................................23

2.1 Drivers ...................................................................................................................................23

2.1.1 Increase in the Ageing Population and Lengthening Life Expectancies........................23

2.1.2 Rising Affluence in Emerging Markets ..........................................................................23

2.1.3 Widespread Prevalence of Chronic Diseases................................................................23

2.2 Restraints ..............................................................................................................................24

2.2.1 Government Policies Aimed at Lowering Prescription Drug Prices ..............................24

2.2.2 Generics and Biosimilars Drugs Hampering Prescription Pharmaceuticals Growth.....24

2.3 Opportunities........................................................................................................................25

2.3.1 Emerging Markets are key Pockets...............................................................................25

2.3.2 Increased Healthcare Awareness..................................................................................25

2.4 Trends ...................................................................................................................................25

2.4.1 Increased Spending on Specialty Medicines – Hepatitis, Autoimmune Diseases, andOncology 25

3 Industry Analysis ...........................................................................................................................26

3.1 Supply Chain Analysis............................................................................................................26

3.2 Regulatory Analysis ...............................................................................................................29

3.3 Macroeconomic Indicators ...................................................................................................30

SAMPLE

3

3.3.1 Healthcare Spending (US$ Billion), by Regions (2005 to 2014) ....................................30

3.3.2 Per Capita Healthcare Spending (US$), by Regions (2005 to 2014)..............................30

3.3.3 Public Healthcare Spending (US$ Billion), by Regions (2005 to 2014)..........................30

3.4 Ecosystem Analysis ...............................................................................................................31

3.4.1 Market Size of Top-25 Prescription Pharmaceuticals (2013 to 2015) ..........................31

3.4.2 Therapeutic Segments Benchmarking ..........................................................................32

4 Prescription Pharmaceuticals Markets, by Therapeutic Segments ..............................................34

4.1 Introduction ..........................................................................................................................34

4.1.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByTherapeutic Segments (2015) .......................................................................................................34

4.1.2 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByTherapeutic Segments (2013 – 2020) ...........................................................................................34

4.2 Cardiovascular Disorders ......................................................................................................35

4.2.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByCardiovascular Disorders, (2013 – 2020) ......................................................................................36

4.2.2 Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size &Forecast (US$ billion), By Regions (2015 vs. 2020) .......................................................................36

4.2.3 Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size &Forecast (US$ billion), By Regions (2013 – 2020) .........................................................................37

4.2.4 North America Prescription Pharmaceuticals for Cardiovascular Disorders Market Size& Forecast (US$ billion), By Country (2013 – 2020) .....................................................................37

4.2.5 Europe Prescription Pharmaceuticals for Cardiovascular Disorders Market Size &Forecast (US$ billion), By Country (2013 – 2020) .........................................................................38

4.2.6 Asia Prescription Pharmaceuticals for Cardiovascular Disorders Market Size (US$Billion) & Forecast (US$ billion), By Country (2013 – 2020) .........................................................38

4.2.7 Rest of the World (RoW) Prescription Pharmaceuticals for Cardiovascular DisordersMarket Size & Forecast (US$ billion), By Country (2013 – 2020)..................................................38

4.3 Oncology ...............................................................................................................................39

4.3.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Oncology(2013 – 2020) ................................................................................................................................39

4.3.2 Global Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$billion), By Regions (2015 vs. 2020) ..............................................................................................40

4.3.3 Global Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$billion), By Regions (2013 – 2020).................................................................................................40

4.3.4 North America Prescription Pharmaceuticals for Oncology Market Size & Forecast(US$ billion), By Country (2013 – 2020)........................................................................................41

SAMPLE

4

4.3.5 Europe Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$billion), By Country (2013 – 2020) ................................................................................................41

4.3.6 Asia Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion),By Country (2013 – 2020) .............................................................................................................42

4.3.7 Rest of the World (RoW) Prescription Pharmaceuticals for Oncology Market Size &Forecast (US$ billion), By Country (2013 – 2020) .........................................................................42

4.4 Inflammatory Conditions ......................................................................................................42

4.4.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByInflammatory Conditions (2013 – 2020) .......................................................................................43

4.4.2 Global Prescription Pharmaceuticals Market Size & Forecast for InflammatoryConditions (US$ billion), By Regions (2015 vs. 2020) ...................................................................43

4.4.3 Global Prescription Pharmaceuticals Market Size & Forecast for InflammatoryConditions (US$ billion), By Regions (2013 – 2020)......................................................................44

4.4.4 North America Prescription Pharmaceuticals Market Size & Forecast for InflammatoryConditions (US$ billion), By Country (2013 – 2020)......................................................................44

4.4.5 Europe Prescription Pharmaceuticals Market Size & Forecast for InflammatoryConditions (US$ billion), By Country (2013 – 2020)......................................................................45

4.4.6 Asia Prescription Pharmaceuticals Market Size & Forecast for InflammatoryConditions (US$ billion), By Country (2013 – 2020)......................................................................45

4.4.7 Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forInflammatory Conditions (US$ billion), By Country (2013 – 2020)...............................................45

4.5 Infectious Diseases................................................................................................................46

4.5.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByInfectious Diseases (2013 – 2020) ................................................................................................46

4.5.2 Global Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases(US$ billion), By Regions (2015 vs. 2020)......................................................................................47

4.5.3 Global Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases(US$ billion), By Regions (2013 – 2020) ........................................................................................47

4.5.4 North America Prescription Pharmaceuticals Market Size & Forecast for InfectiousDiseases (US$ billion), By Country (2013 – 2020) .........................................................................48

4.5.5 Europe Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases(US$ billion), By Country (2013 – 2020)........................................................................................48

4.5.6 Asia Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$billion), By Country (2013 – 2020) ................................................................................................48

4.5.7 Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forInfectious Diseases (US$ billion), By Country (2013 – 2020) ........................................................49

4.6 Metabolic Disorders..............................................................................................................49

SAMPLE

5

4.6.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByMetabolic Disorders (2013 – 2020)...............................................................................................49

4.6.2 Global Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders(US$ billion), By Regions (2015 vs. 2020)......................................................................................50

4.6.3 Global Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders(US$ billion), By Regions (2013 – 2020) ........................................................................................50

4.6.4 North America Prescription Pharmaceuticals Market Size & Forecast for MetabolicDisorders (US$ billion), By Country (2013 – 2020) .......................................................................51

4.6.5 Europe Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders(US$ billion), By Country (2013 – 2020)........................................................................................51

4.6.6 Asia Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders(US$ billion), By Country (2013 – 2020)........................................................................................51

4.6.7 Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forMetabolic Disorders (US$ billion), By Country (2013 – 2020) ......................................................52

4.7 Respiratory Disorders ...........................................................................................................52

4.7.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByRespiratory Disorders (2013 – 2020) ............................................................................................52

4.7.2 Global Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders(US$ billion), By Regions (2015 vs. 2020)......................................................................................53

4.7.3 Global Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders(US$ billion), By Regions (2013 – 2020) ........................................................................................53

4.7.4 North America Prescription Pharmaceuticals Market Size & Forecast for RespiratoryDisorders (US$ billion), By Country (2013 – 2020) .......................................................................54

4.7.5 Europe Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders(US$ billion), By Country (2013 – 2020)........................................................................................54

4.7.6 Asia Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders(US$ billion), By Country (2013 – 2020)........................................................................................55

4.7.7 Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forRespiratory Disorders (US$ billion), By Country (2013 – 2020) ....................................................55

4.8 Other Therapeutic Segments ................................................................................................55

4.8.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By OtherTherapeutic Segments (2013 – 2020) ...........................................................................................56

4.8.2 Global Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Regions (2015 vs. 2020) .....................................................................56

4.8.3 Global Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Regions (2013 – 2020) .......................................................................57

SAMPLE

6

4.8.4 North America Prescription Pharmaceuticals Market Size & Forecast for OtherTherapeutic Segments (US$ billion), By Country (2013 – 2020)...................................................57

4.8.5 Europe Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Country (2013 – 2020) .......................................................................57

4.8.6 Asia Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Country (2013 – 2020) .......................................................................58

4.8.7 Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forOther Therapeutic Segments (US$ billion), By Country (2013 – 2020) ........................................58

5 Prescription Pharmaceuticals Markets, by Formulations .............................................................59

5.1 Introduction ..........................................................................................................................59

5.1.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByFormulations (2015)......................................................................................................................59

5.1.2 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByFormulations (2013 – 2020)..........................................................................................................59

5.2 Capsules ................................................................................................................................60

5.2.1 Global Capsules Market Size & Forecast (US$ billion) (2013 – 2020)...........................60

5.2.2 Global Capsules Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) .....61

5.2.3 Global Capsules Market Size & Forecast (US$ billion), By Regions (2013 – 2020) .......61

5.3 Tablets...................................................................................................................................62

5.3.1 Global Tablets Market Size & Forecast (US$ billion), (2013 – 2020) ............................62

5.3.2 Global Tablets Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) .......62

5.3.3 Global Tablets Market Size & Forecast (US$ billion), By Regions (2013 – 2020)..........63

5.4 Inhalants and Liquids ............................................................................................................63

5.4.1 Global Inhalants and Liquids Market Size & Forecast (US$ billion), (2013 – 2020)......64

5.4.2 Global Inhalants and Liquids Market Size & Forecast (US$ billion), By Regions (2015 vs.2020) 64

5.4.3 Global Inhalants and Liquids Market Size & Forecast (US$ billion), By Regions (2013 –2020) 65

5.5 Parenterals ............................................................................................................................65

5.5.1 Global Parenteral Market Size Market Size & Forecast (US$ billion), (2013 – 2020) ...65

5.5.2 Global Parenteral Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) ..66

5.5.3 Global Parenterals Market Size & Forecast (US$ billion), By Regions (2013 – 2020) ...66

5.6 Topicals .................................................................................................................................67

5.6.1 Global Topicals Market Size & Forecast (US$ billion), (2013 – 2020) ...........................67

SAMPLE

7

5.6.2 Global Topicals Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) ......67

5.6.3 Global Topicals Market Size & Forecast (US$ billion), By Regions (2013 – 2020) ........68

6 Geographic Analysis ......................................................................................................................69

6.1 Introduction ..........................................................................................................................69

6.1.1 Global Prescription Pharmaceuticals Market Size vs. CAGR% (2015 – 2020), By Regions.......................................................................................................................................69

6.1.2 Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Regions(2013 – 2020) ................................................................................................................................69

6.2 North America.......................................................................................................................70

6.2.1 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByCountry (2013 – 2020) ..................................................................................................................70

6.2.2 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion),(2013 – 2020) ................................................................................................................................70

6.2.3 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByTherapeutic Segments (2013 – 2020) ...........................................................................................71

6.2.4 North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByFormulations (2013 – 2020)..........................................................................................................72

6.3 Europe...................................................................................................................................73

6.3.1 Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country(2013 – 2020) ................................................................................................................................73

6.3.2 Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 –2020) .......................................................................................................................................73

6.3.3 Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByTherapeutic Segments (2013 – 2020) ...........................................................................................74

6.3.4 Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByFormulations (2013 – 2020)..........................................................................................................74

6.4 Asia........................................................................................................................................75

6.4.1 Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country(2013 – 2020) ................................................................................................................................75

6.5 Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 – 2020).....75

6.5.1 Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByTherapeutic Segments (2013 – 2020) ...........................................................................................76

6.5.2 Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByFormulations (2013 – 2020)..........................................................................................................76

6.6 Rest of the World (RoW).......................................................................................................77

SAMPLE

8

6.6.1 RoW Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country,(2013 – 2020) ................................................................................................................................77

6.6.2 Row Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 – 2020).......................................................................................................................................77

6.6.3 RoW Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByTherapeutic Segments (2013 – 2020) ...........................................................................................78

6.6.4 RoW Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByFormulations (2013 – 2020)..........................................................................................................78

7 Competitive Landscape.................................................................................................................80

7.1 Market Share Analysis...........................................................................................................80

7.2 Market Positioning of Key Players ........................................................................................80

8 Company Profiles ..........................................................................................................................81

8.1 AstraZeneca (U.K.) ................................................................................................................81

8.1.1 Financial Overview: AstraZeneca plc (U.K.) (Europe) (2013 to 2015)...........................81

8.1.2 Revenues of Top-3 Pharmaceutical Products AstraZeneca plc (U.K.) (Europe) (2013 to2015) 82

8.2 Bayer AG (Germany) .............................................................................................................82

8.2.1 Financial Overview: Bayer AG (Germany) (Europe) (2013 to 2015) .............................83

8.2.2 Revenues of Top-3 Pharmaceutical Products: Bayer AG (Germany) (Europe) (2013 to2015) .......................................................................................................................................83

8.3 Gilead Sciences (U.S.)............................................................................................................84

8.3.1 Financial Overview: Gilead Sciences, Inc. (U.S.) (2013 to 2015) ...................................84

8.3.2 Revenues of Top-3 Pharmaceutical Products: Gilead Sciences, Inc. (U.S.) (2013 to2015) .......................................................................................................................................85

8.4 GlaxoSmithKline (U.K.) ..........................................................................................................85

8.4.1 Financial Overview: GlaxoSmithKline plc (U.K.) (Europe) (2013 to 2015) ....................85

8.4.2 Revenues of Top-3 Pharmaceutical Products: GlaxoSmithKline plc (U.K.) (Europe)(2013 to 2015)...............................................................................................................................86

8.5 Johnson & Johnson (U.S.)......................................................................................................87

8.5.1 Financial Overview: Johnson & Johnson (U.S.) (2013 to 2015) ....................................87

8.5.2 Revenues of Top-3 Pharmaceutical Products: Johnson & Johnson (U.S.) (2013 to 2015).......................................................................................................................................88

8.6 Merck & Co (U.S)...................................................................................................................88

8.6.1 Financial Overview: Merck & Co., Inc. (U.S.) (2013 to 2015)........................................88

SAMPLE

9

8.6.2 Revenues of Top-3 Pharmaceutical Products: Merck & Co., Inc. (U.S.) (2013 to 2015)89

8.7 Novartis A.G. (Switzerland) ...................................................................................................90

8.7.1 Financial Overview: Novartis AG (Switzerland) (Europe) (2013 to 2015).....................90

8.7.2 Revenues of Top-3 Pharmaceutical Products: Novartis AG (Switzerland) (Europe)(2013 to 2015)...............................................................................................................................91

8.8 Pfizer (U.S.)............................................................................................................................91

8.8.1 Financial Overview: Pfizer Inc. (U.S.) (2013 to 2015)....................................................91

8.8.2 Revenues of Top-3 Pharmaceutical Products: Pfizer Inc. (U.S.) (2013 to 2015) ...........92

8.9 F. Hoffmann-La Roche (Switzerland) ....................................................................................93

8.9.1 Financial Overview: F. Hoffmann-La Roche (Switzerland) (Europe) (2013 to 2015) ....93

8.9.2 Revenues of Top-3 Pharmaceutical Products: Hoffmann-La Roche (Switzerland)(Europe) (2013 to 2015)................................................................................................................94

8.10 Sanofi S.A.(France) ................................................................................................................94

8.10.1 Financial Overview: Sanofi S.A. (France) (Europe) (2013 to 2015) ...............................94

8.10.2 Revenues of Top-3 Pharmaceutical Products: Sanofi S.A. (France) (Europe) (2013 to2015) .......................................................................................................................................95

9 SCALAR 360 DEGREE MARKET REVIEW.........................................................................................96

10 Appendix .......................................................................................................................................96

10.1 Acronyms ..............................................................................................................................96

10.2 Contact Us................................................................................ Error! Bookmark not defined.

10.3 Disclaimer................................................................................. Error! Bookmark not defined.SAMPLE

10

Table 1. Global Prescription Pharmaceuticals Market ...................................................................19

Table 2. Global Prescription Pharmaceuticals Market Size (US$ Billion), By Therapeutic Segments(2015 vs. 2020)......................................................................................................................................20

Table 3...................................................................................................................................................20

Table 4. Global Prescription Pharmaceuticals Market Size (US$ Billion), By Formulations (2015 vs.2020) 21

Table 5. Global Prescription Pharmaceuticals Market Size (US$ Billion), By Regions (2015 vs.2020) 21

Table 6. Healthcare Spending (US$ Billion), by Regions (2005 to 2014) ........................................30

Table 7. Per Capita Healthcare Spending (US$), by Regions (2005 to 2014)..................................30

Table 8. Public Healthcare Spending (US$ Billion), by Regions (2005 to 2014)..............................30

Table 9. Market Size of Top-25 Prescription Pharmaceuticals (2013 to 2015) ..............................31

Table 10. Therapeutic Segments Benchmarking ..............................................................................32

Table 11. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By TherapeuticSegments (2013 – 2020) .......................................................................................................................34

Table 12. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByCardiovascular Disorders, (2013 – 2020) ..............................................................................................36

Table 13. Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast(US$ billion), By Regions (2013 – 2020) ................................................................................................37

Table 14. North America Prescription Pharmaceuticals for Cardiovascular Disorders Market Size &Forecast (US$ billion), By Country (2013 – 2020) .................................................................................37

Table 15. Europe Prescription Pharmaceuticals for Cardiovascular Disorders Market Size &Forecast (US$ billion), By Country (2013 – 2020) .................................................................................38

Table 16. Asia Prescription Pharmaceuticals for Cardiovascular Disorders Market Size (US$ Billion)for Asia, By Country (2013 – 2020) .......................................................................................................38

Table 17. Rest of the World (RoW) Prescription Pharmaceuticals for Cardiovascular DisordersMarket Size & Forecast (US$ billion), By Country (2013 – 2020) .........................................................38

Table 18. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Oncology(2013 – 2020) ........................................................................................................................................39

Table 19. Global Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion),By Regions (2013 – 2020)......................................................................................................................40

Table 20. North America Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$billion), By Country (2013 – 2020) ........................................................................................................41

Table 21. Europe Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion),By Country (2013 – 2020) .....................................................................................................................41

SAMPLE

11

Table 22. Asia Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion), ByCountry (2013 – 2020) ..........................................................................................................................42

Table 23. Rest of the World (RoW), Prescription Pharmaceuticals for Oncology Market Size &Forecast (US$ billion),By Country (2013 – 2020) ..................................................................................42

Table 24. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByInflammatory Conditions (2013 – 2020)...............................................................................................43

Table 25. Global Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions(US$ billion), By Regions (2013 – 2020) ................................................................................................44

Table 26. North America Prescription Pharmaceuticals Market Size & Forecast for InflammatoryConditions (US$ billion), By Country (2013 – 2020)..............................................................................44

Table 27. Europe Prescription Pharmaceuticals Market Size & Forecast for InflammatoryConditions (US$ billion), By Country (2013 – 2020)..............................................................................45

Table 28. Asia Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions(US$ billion), By Country (2013 – 2020)................................................................................................45

Table 29. Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forInflammatory Conditions (US$ billion), By Country (2013 – 2020).......................................................45

Table 30. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By InfectiousDiseases (2013 – 2020) .........................................................................................................................46

Table 31. Global Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$billion), By Regions (2015 vs. 2020) ......................................................................................................47

Table 32. Global Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$billion), By Regions (2013 – 2020).........................................................................................................47

Table 33. North America Prescription Pharmaceuticals Market Size & Forecast for InfectiousDiseases (US$ billion), By Country (2013 – 2020) .................................................................................48

Table 34. Europe Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases(US$ billion), By Country (2013 – 2020)................................................................................................48

Table 35. Asia Prescription Pharmaceuticals Market Size & Forecast for Infectious Diseases (US$billion), By Country (2013 – 2020) ........................................................................................................48

Table 36. Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forInfectious Diseases (US$ billion), By Country (2013 – 2020) ................................................................49

Table 37. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By MetabolicDisorders (2013 – 2020)........................................................................................................................49

Table 38. Global Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders(US$ billion), By Regions (2013 – 2020) ................................................................................................50

Table 39. North America Prescription Pharmaceuticals Market Size & Forecast for MetabolicDisorders (US$ billion), By Country (2013 – 2020) ...............................................................................51

Table 40. Europe Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders(US$ billion), By Country (2013 – 2020)................................................................................................51

SAMPLE

12

Table 41. Asia Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders (US$billion), By Country (2013 – 2020) ........................................................................................................51

Table 42. Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forMetabolic Disorders (US$ billion), By Country (2013 – 2020) ..............................................................52

Table 43. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By RespiratoryDisorders (2013 – 2020)........................................................................................................................52

Table 44. Global Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders(US$ billion), By Regions (2013 – 2020) ................................................................................................53

Table 45. North America Prescription Pharmaceuticals Market Size & Forecast for RespiratoryDisorders (US$ billion), By Country (2013 – 2020) ...............................................................................54

Table 46. Europe Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders(US$ billion), By Country (2013 – 2020)................................................................................................54

Table 47. Asia Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders (US$billion), By Country (2013 – 2020) ........................................................................................................55

Table 48. Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast forRespiratory Disorders (US$ billion), By Country (2013 – 2020)............................................................55

Table 49. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By OtherTherapeutic Segments (2013 – 2020) ...................................................................................................56

Table 50. Global Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Regions (2013 – 2020) ...............................................................................57

Table 51. North America Prescription Pharmaceuticals Market Size & Forecast for OtherTherapeutic Segments (US$ billion), By Country (2013 – 2020)...........................................................57

Table 52. Europe Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Country (2013 – 2020) ...............................................................................57

Table 53. Asia Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Country (2013 – 2020) ...............................................................................58

Table 54. Rest of the World (RoW) Prescription Pharmaceuticals Market Size & Forecast for OtherTherapeutic Segments (US$ billion), By Country (2013 – 2020)...........................................................58

Table 55. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByFormulations (2013 – 2020)..................................................................................................................59

Table 56. Global Capsules Market Size & Forecast (US$ billion) (2013 – 2020)...............................60

Table 57. Global Capsules Market Size & Forecast (US$ billion), By Regions (2013 – 2020) ...........61

Table 58. Global Tablets Market Size & Forecast (US$ billion), (2013 – 2020) ................................62

Table 59. Global Tablets Market Size & Forecast (US$ billion), By Regions (2013 – 2020)..............63

Table 60. Global Inhalants and Liquids Market Size & Forecast (US$ billion), (2013 – 2020)..........64

Table 61. Global Inhalants and Liquids Market Size & Forecast (US$ billion), By Regions (2013 –2020) 65

SAMPLE

13

Table 62. Global Parenteral Market Size & Forecast (US$ billion), (2013 – 2020) ...........................65

Table 63. Global Parenterals Market Size & Forecast (US$ billion), By Regions (2013 – 2020) ......66

Table 64. Global Topicals Market Size & Forecast (US$ billion), (2013 – 2020) ...............................67

Table 65. Global Topicals Market Size & Forecast (US$ billion), By Regions (2013 – 2020) ............68

Table 66. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Regions(2013 – 2020) ........................................................................................................................................69

Table 67. North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByCountry (2013 – 2020) ..........................................................................................................................70

Table 68. North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013– 2020) 70

Table 69. North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByTherapeutic Segments (2013 – 2020) ...................................................................................................71

Table 70. North America Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByFormulations (2013 – 2020)..................................................................................................................72

Table 71. Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country(2013 – 2020) ........................................................................................................................................73

Table 72. Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 – 2020)73

Table 73. Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByTherapeutic Segments (2013 – 2020) ...................................................................................................74

Table 74. Europe Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByFormulations (2013 – 2020)..................................................................................................................74

Table 75. Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country (2013– 2020) 75

Table 76. Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 – 2020).75

Table 77. Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By TherapeuticSegments (2013 – 2020) .......................................................................................................................76

Table 78. Asia Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations(2013 – 2020) ........................................................................................................................................76

Table 79. RoW Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Country,(2013 – 2020) ........................................................................................................................................77

Table 80. RoW Prescription Pharmaceuticals Market Size & Forecast (US$ billion), (2013 – 2020)77

Table 81. RoW Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By TherapeuticSegments (2013 – 2020) .......................................................................................................................78

Table 82. RoW Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By Formulations(2013 – 2020) ........................................................................................................................................78

SAMPLE

14

Table 83. Financial Overview: AstraZeneca plc (U.K.) (Europe) (2013 to 2015)...............................81

Table 84. Revenues of Top-3 Pharmaceutical Products AstraZeneca plc (U.K.) (Europe) (2013 to2015) ...........................................................................................................................................82

Table 85. Financial Overview: Bayer AG (Germany) (Europe) (2013 to 2015) .................................83

Table 86. Revenues of Top-3 Pharmaceutical Products: Bayer AG (Germany) (Europe) (2013 to2015) ...........................................................................................................................................83

Table 87. Financial Overview: Gilead Sciences, Inc. (U.S.) (2013 to 2015) .......................................84

Table 88. Revenues of Top-3 Pharmaceutical Products: Gilead Sciences, Inc. (U.S.) (2013 to 2015) .............................................................................................................................................85

Table 89. Financial Overview: GlaxoSmithKline plc (U.K.) (Europe) (2013 to 2015) ........................85

Table 90. Revenues of Top-3 Pharmaceutical Products: GlaxoSmithKline plc (U.K.) (Europe) (2013to 2015) ...........................................................................................................................................86

Table 91. Financial Overview: Johnson & Johnson (U.S.) (2013 to 2015) ........................................87

Table 92. Revenues of Top-3 Pharmaceutical Products: Johnson & Johnson (U.S.) (2013 to 2015) 88

Table 93. Financial Overview: Merck & Co., Inc. (U.S.) (2013 to 2015)............................................88

Table 94. Revenues of Top-3 Pharmaceutical Products: Merck & Co., Inc. (U.S.) (2013 to 2015) ...89

Table 95. Financial Overview: Novartis AG (Switzerland) (Europe) (2013 to 2015).........................90

Table 96. Revenues of Top-3 Pharmaceutical Products: Novartis AG (Switzerland) (Europe) (2013to 2015) ...........................................................................................................................................91

Table 97. Financial Overview: Pfizer Inc. (U.S.) (2013 to 2015)........................................................91

Table 98. Revenues of Top-3 Pharmaceutical Products: Pfizer Inc. (U.S.) (2013 to 2015) ...............92

Table 99. Financial Overview: F. Hoffmann-La Roche (Switzerland) (Europe) (2013 to 2015) ........93

Table 100. Revenues of Top-3 Pharmaceutical Products: Hoffmann-La Roche (Switzerland)(Europe) (2013 to 2015)........................................................................................................................94

Table 101. Financial Overview: Sanofi S.A. (France) (Europe) (2013 to 2015) ...............................94

Table 102. Revenues of Top-3 Pharmaceutical Products: Sanofi S.A. (France) (Europe) (2013 to2015) .......................................................................................................................................95

Table 103. Acronyms ......................................................................................................................96

SAMPLE

15

List of Figures

Figure 1. Research Methodology .....................................................................................................16

Figure 2. Prescription Pharmaceuticals Market Segmentation .......................................................17

Figure 3. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), By TherapeuticSegments (2015) ...................................................................................................................................34

Figure 4. Global Prescription Pharmaceuticals for Cardiovascular Disorders Market Size & Forecast(US$ billion), By Regions (2015 vs. 2020)..............................................................................................36

Figure 5. Global Prescription Pharmaceuticals for Oncology Market Size & Forecast (US$ billion),By Regions (2015 vs. 2020) ...................................................................................................................40

Figure 6. Global Prescription Pharmaceuticals Market Size & Forecast for Inflammatory Conditions(US$ billion), By Regions (2015 vs. 2020)..............................................................................................43

Figure 7. Global Prescription Pharmaceuticals Market Size & Forecast for Metabolic Disorders(US$ billion), By Regions (2015 vs. 2020)..............................................................................................50

Figure 8. Global Prescription Pharmaceuticals Market Size & Forecast for Respiratory Disorders(US$ billion), By Regions (2015 vs. 2020)..............................................................................................53

Figure 9. Global Prescription Pharmaceuticals Market Size & Forecast for Other TherapeuticSegments (US$ billion), By Regions (2015 vs. 2020).............................................................................56

Figure 10. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion), ByFormulations (2015)..............................................................................................................................59

Figure 11. Global Capsules Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) ....61

Figure 12. Global Tablets Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020).......62

Figure 13. Global Inhalants and Liquids Market Size & Forecast (US$ billion), By Regions (2015vs. 2020) .......................................................................................................................................64

Figure 14. Global Parenteral Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) .66

Figure 15. Global Topicals Market Size & Forecast (US$ billion), By Regions (2015 vs. 2020) ......67

Figure 16. Global Prescription Pharmaceuticals Market Size vs. CAGR% (2015 – 2020), By Regions.......................................................................................................................................69

Figure 17. Market Share Analysis...................................................................................................80

Figure 18. Market Positioning of Key Players ................................................................................80

SAMPLE

16

Market Overview

1.1 DefinitionsThe 'Global Prescription Pharmaceuticals Market – Market Size and Forecast (2013–

2020)' report includes market size and forecast estimates for the period 2013 to

2020. The scope of this report is cardiovascular disorders, inflammatory conditions,

metabolic disorders, oncology, respiratory disorders, and other therapeutic

segments. The report segments the market by therapeutic segments, formulations,

and regions. The report includes market size and forecast estimates for all market

segments in the study period. The report has 2015 as the base year, 2013 and 2014

as the historic years, and 2020 as the forecast year.

The therapeutic segments that are included in this report are cardiovascular

disorders, infectious diseases, inflammatory conditions, metabolic disorders,

oncology, respiratory disorders, and other therapeutic segments. The formulation

segments that are included in this report are capsules, inhalants, parenteral, tablets,

and topicals. The regional market segments included in the report are Asia, Europe,

North America, and Rest of the World.

1.2 Research MethodologyThe research methodology for market research reports at ScalarMR includes a

combination of top-down and bottom-up research formats. Continuous market

tracking, rigorous fact-checking, data-triangulation, and multiple layers of quality

control ensure high-quality data that can be leveraged for actionable insights.

ScalarMR’s research methodology starts with extensive secondary, research.

Important secondary sources include SEC filings, annual reports, financial reports,

investor presentations, and technical & industry publications. Secondary research

helps build a comprehensive map of the structure of the market. It helps identify key

players in all market segments and helps build their profiles by identifying their

financials, product portfolios, and growth strategies. It also identifies qualitative

market factors like regulatory scenario, patent estates, and market developments.

Figure 1. Research Methodology

SAMPLE

17

A bottom-up market sizing format is used to arrive at the top-line market size.

Revenues of key market players used to arrive at the market-specific revenues of

each key market player. A process of inward bracketing is used to arrive at the

market-specific revenues for each key market player. The market specific revenues

are combined to arrive at the top-line global market size. Segment-specific and

regional market sizes are estimated through top-down market sizing.

Data synthesis and triangulation techniques are used to develop the market model.

The model represents current consensus market opinion. The market estimates from

the model are used to generate reports that include qualitative and quantitative

insights into the market.

1.3 Market Segmentation

Figure 2. Prescription Pharmaceuticals Market Segmentation

GlobalMarket

Size

Market-specificRevenues of Key Market

Players

Revenues of Key Market Players

Global MarketSize

Segment-specificMarket Size

RegionalMarket

Size

Bottom-up

Top-down

Prescription Pharmaceuticals Market, byTherapeutic Segments

CardiovascularDisorders

InfectiousDiseases

InflammatoryConditions

MetabolicDisorders Oncology Respiratory

DisordersOther

TherapeuticSegments

SAMPLE

18

Prescription Pharmaceuticals Market, byFormulations

Capsules Inhalants Parenterals Tablets Topicals

Prescription Pharmaceuticals Market, byRegions

Asia Europe North America Rest of the World

SAMPLE

19

1 Executive SummaryThe global prescription pharmaceutical market was estimated to be US$ 726.89

billion in 2015. This market is expected to grow at a CAGR of 4.80% in the forecast

period and is expected to be US$ 918.74 billion in 2020. This report segments the

prescription pharmaceuticals market by therapeutic segments, formulations and

regions.

1.1 Global Prescription Pharmaceuticals Market

Table 1. Global Prescription Pharmaceuticals Market

Global Prescription PharmaceuticalsMarket

Market Size (US$ billion) CAGR%(2015 – 2020)2015 2020

Total 726.89 918.74 4.80

Ther

apeu

tic S

egm

ents

Cardiovascular Disorders

Oncology

Inflammatory Conditions

Infectious Diseases

Metabolic Disorders

Respiratory Disorders

Other Therapeutic Segments

Form

ulat

ions

Capsules

Tablets

Inhalants and Liquids

Parenterals

Topicals

Regi

ons

North America

Europe

Asia

RoW

Source: Scalar Market Research Analysis

SAMPLE

20

1.2 Global Prescription Pharmaceuticals Market Size (US$ Billion), ByTherapeutic Segments (2015 vs. 2020)

Table 2. Global Prescription Pharmaceuticals Market Size (US$ Billion), ByTherapeutic Segments (2015 vs. 2020)

Table 3.


The therapeutic segments of the prescription pharmaceuticals market included in this

report are cardiovascular disorders, oncology, inflammatory conditions, infectious

diseases, metabolic disorders, respiratory disorders, and other therapeutic

segments. Cardiovascular disorders were the largest therapeutic segment in 2015.

This segment was estimated to be US$ XX billion in 2015. On the other hand,

infectious diseases are expected to be the fastest-growing therapeutic segment in

the forecast period. This market segment is expected to grow at a CAGR of XX%

between 2015 and 2020.

129.

05

117.

53

110.

28

95.3

8

83.4

4

36.8

7

154.

34

157.

91

152.

20

138.

36

125.

62

107.

55

44.0

6

193.

03

4.12

5.314.64

5.66 5.21

3.63

4.58

CardiovascularDisorders

Oncology InflammatoryConditions

InfectiousDiseases

MetabolicDisorders

RespiratoryDisorders

Other TherapeuticSegments

CAGR

% (2

015

–20

20)

Mar

ket S

ize (U

SD B

illio

n)

2015 2020 CAGR% (2015 – 2020)

SAMPLE

21

1.3 Global Prescription Pharmaceuticals Market Size (US$ Billion), ByFormulations (2015 vs. 2020)

Table 4. Global Prescription Pharmaceuticals Market Size (US$ Billion), ByFormulations (2015 vs. 2020)


The formulation segments of the prescription pharmaceuticals market included in this

report are capsules, tablets, inhalants and liquids, parenteral, and topicals. Capsules

were the largest formulation segment in 2015. This segment was estimated to be

US$ XX billion in 2015. It is also expected to be the fastest-growing formulation

segment in the forecast period. This market segment is expected to grow at a CAGR

of XX% between 2015 and 2020.

1.4 Global Prescription Pharmaceuticals Market Size (US$ Billion), ByRegions (2015 vs. 2020)

Table 5. Global Prescription Pharmaceuticals Market Size (US$ Billion), ByRegions (2015 vs. 2020)

269.

45

247.

42

103.

69

71.3

4

34.9

9

356.

16

304.

42

127.

34

89.7

6

41.0

6

5.74

4.23 4.194.70

3.26

Capsules Tablets Inhalants andLiquids

Parenterals Topicals

CAGR

% (2

015

–20

20)

Mar

ket S

ize (U

SD B

illio

n)

2015 2020 CAGR% (2015 – 2020)

295.

77

183.

98

158.

10

89.0

4

364.

41

219.

20

219.

73

115.

40

4.263.57

6.80

5.32

North America Europe Asia RoW

CAGR

% (2

015

–20

20)

Mar

ket S

ize (U

SD B

illio

n)

2015 2020 CAGR% (2015 – 2020)

SAMPLE

22


The regional segments of the prescription pharmaceuticals market included in this

report are North America, Europe, Asia, and Rest of the World (RoW). North

America was the largest regional segment in 2015. This segment was estimated to

be US$ XX billion in 2015. On the other hand, Asia is expected to be the fastest-

growing regional segment in the forecast period. This market segment is expected to

grow at a CAGR of XX% between 2015 and 2020.

SAMPLE

23

2 Market Overview

2.1 Drivers

2.1.1 Increase in the Ageing Population and Lengthening Life ExpectanciesAccording to the World Health Organization (WHO), in 2010 around 8% of the global

population was aged 65 years and above. In 2015, the elderly population comprised

around 12% of the global population. It has been estimated that by 2050, about 2.1

billion people will be aged above 60 years. The evolution of the population structure

will lead to increased pressure on long-term publicly-funded health, support

programmes for older people. There will be a paradigm shift from acute to chronic

illnesses thereby leading to an increased use of prescription pharmaceuticals.

The rising life expectancy within the older population segment is leading to an

increase in the number and proportion of people at very old ages. People aged 85 or

older constitute around 12% and 6% of world’s 65 and above population in

developed and developing economies respectively. According to Economist

Intelligence Unit (EIU), life expectancy is expected to increase from an estimated

72.7 years in 2013 to 73.7 years by 2018. This will result in a rise in global health

care and life sciences spending.

2.1.2 Rising Affluence in Emerging MarketsGrowing consumer wealth and income levels, increasing government and patient

awareness, and a trend towards healthier lifestyles are anticipated to boost health

care spending to around 8.1% between 2014 and-2018 in Asia. Factors such as

government focus on broader welfare policies and economic expansion will drive the

market for prescription pharmaceuticals. BRICS (Brazil, Russia, India, China, and

South Africa) are among the fastest-growing global economies. According to the

World Economic Forum report, by 2022 around one-third of all global health

expenditure will occur in emerging economies. Increased healthcare spending and

improved access to healthcare in emerging economies will drive the global

prescription pharmaceuticals market.

2.1.3 Widespread Prevalence of Chronic DiseasesChronic diseases namely, heart disease, stroke, cancer, type 2 diabetes, obesity,

and arthritis pose a serious threat to the health of world population. The mortality

SAMPLE

30

formation of the ASEAN Economic Community (AEC) to define the regulatory

landscape for this region.

Thus, across the globe, a strong trend is being observed towards consolidation of

legislature systems into a global drug safety system with balanced business

processes.

3.3 Macroeconomic Indicators

3.3.1 Healthcare Spending (US$ Billion), by Regions (2005 to 2014)Table 6. Healthcare Spending (US$ Billion), by Regions (2005 to 2014)

Regions 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 CAGR%(2005–2014)

Asia

Europe

North America

Rest of the World

Total

Source: World Bank and Scalar Market Research Analysis

3.3.2 Per Capita Healthcare Spending (US$), by Regions (2005 to 2014)Table 7. Per Capita Healthcare Spending (US$), by Regions (2005 to 2014)

Regions 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 CAGR%(2005–2014)

Asia

Europe

North America

Rest of the World

Total


3.3.3 Public Healthcare Spending (US$ Billion), by Regions (2005 to 2014)Table 8. Public Healthcare Spending (US$ Billion), by Regions (2005 to 2014)

SAMPLE

31

Regions 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 CAGR%(2005–2014)

Asia

Europe

North America

Rest of the World

Total


3.4 Ecosystem Analysis

3.4.1 Market Size of Top-25 Prescription Pharmaceuticals (2013 to 2015)Table 9. Market Size of Top-25 Prescription Pharmaceuticals (2013 to 2015)No. Product Company Indication 2015

(US$million)

2014(US$million)

2013(US$million)

AnnualGrowth(2014 to2015)

AnnualGrowth(2013 to2014)

U.S. PatentExpiry

1 Humira AbbVie Inc. (U.S.) Rheumatoidarthritis andotherinflammatoryconditions

14,021 12,543 10,659 11.78% 17.68% December2016

2 Harvoni Gilead Sciences, Inc.(U.S.)

Hepatitis C 13,864 2,127 N.A. 551.81%

N.A. 2030

3 Enbrel Amgen Inc. (U.S.),Pfizer Inc. (U.S.),Takeda PharmaceuticalCompany Ltd. (Japan)

Rheumatoidarthritis,psoriasis, andotherinflammatoryconditions

9,027 8,917 8,742 1.23% 2.00% August2019

4 Remicade Johnson & Johnson(U.S.), Merck & Co.(U.S.), MitsubishiTanabe PharmaCorporation (Japan)

Anti-TNF alphadrug forinflammatorydisorders

8,957 9,889 9,646 -9.42% 2.52% September2018

5 Lantus Sanofi S.A. (France) Diabetes 7,209 7,157 6,448 0.73% 11.00% August2014

6 Avastin F. Hoffmann-La RocheAG (Switzerland)

Cancer 6,905 6,629 6,461 4.16% 2.60% 2019

7 Herceptin F. Hoffmann-La RocheAG (Switzerland)

Cancer 6,754 6,483 6,280 4.18% 3.23% 2019

8 PrevnarFamily

Pfizer Inc. (U.S.) Pneumococcalvaccine

6,245 4,464 3,974 39.90% 12.33% 2026

9 MabThera F. Hoffmann-La Roche Cancer 5,827 5,788 5,950 0.67% -2.72% 2015

SAMPLE

34

4 Prescription Pharmaceuticals Markets, by TherapeuticSegments

4.1 IntroductionThe therapeutic segments of the prescription pharmaceuticals market included in this

report are cardiovascular disorders, oncology, inflammatory conditions, infectious

diseases, metabolic disorders, respiratory disorders, and other therapeutic

segments. Cardiovascular disorders were the largest therapeutic segment in 2015,

while infectious diseases are expected to be the fastest-growing therapeutic

segment in the forecast period.

4.1.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$billion), By Therapeutic Segments (2015)

Figure 3. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion),By Therapeutic Segments (2015)


Cardiovascular disorders, oncology, and inflammatory conditions were the three

largest therapeutic segments of the prescription pharmaceuticals market in 2015.

The combined share of these three therapeutic segments was XX% in 2015.

4.1.2 Global Prescription Pharmaceuticals Market Size & Forecast (US$billion), By Therapeutic Segments (2013 – 2020)

Table 11. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion),By Therapeutic Segments (2013 – 2020)

Therapeutic Segments 2013 2014 2015 2016 2017 2018 2019 2020CAGR%(2015 –2020)


Cardiovascular Disorders | USD 129.05 Billion

Total | USD 726.89 Billion

Oncology | USD 117.53 Billion

Inflammatory Conditions | USD 110.28 Billion

Infectious Diseases | USD 95.38 Billion

Metabolic Disorders | USD 83.44 Billion

Respiratory Disorders | USD 36.87 Billion

Other Therapeutic Segments | USD 154.34 Billion

SAMPLE

35

Oncology


Infectious Diseases

Metabolic Disorders


Other Therapeutic Segments

Total


Cardiovascular disorders were the largest therapeutic segment of the prescription

pharmaceuticals market in 2015. This market segment is expected to grow at a

CAGR of XX% from US$ XX billion in 2015 to US$ XX billion in 2020.

According to 2015 American Heart Association statistics, cardiovascular disorders

account for 17.3 million deaths per year and is expected to grow to over 23.6 million

deaths by 2030. In the year 2011, around 787,000 people in the U.S. died from

stroke, heart disease and other cardiovascular diseases in 2011. The cardiovascular

disorders tend to account for more deaths in comparison to all forms of cancer

combined.

4.2 Cardiovascular DisordersCardiovascular disorder was the largest therapeutic segments in 2015. This segment

includes a wide range of disease categories including hypertension, dyslipidemia,

stroke, atherosclerosis, thrombosis, and coronary artery disease. According to World

Heart Federation, the risk factors for cardiovascular disorders include unchangeable

factors such as age, sex, and heredity, and changeable factors like diet, obesity,

tobacco consumption, stress, and physical inactivity. The rate of cardiovascular

disorders is high in developed and rapidly increasing in developing countries dues to

changes in lifestyle and nutrition.

SAMPLE

36

4.2.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$billion), By Cardiovascular Disorders, (2013 – 2020)

Table 12. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion),By Cardiovascular Disorders, (2013 – 2020)

2013 2014 2015 2016 2017 2018 2019 2020 CAGR%(2015 –2020)

Market Size (US$ Billion)

Annual Growth Rate (%)


The global prescription pharmaceuticals for cardiovascular disorders market grew

from US$ XX billion in 2013 to US$ XX billion in 2015. This market is expected to

grow at an annual growth rate of between XX% and XX% in the forecast period. It is

expected to have a CAGR of XX% between 2015 and 2020.

4.2.2 Global Prescription Pharmaceuticals for Cardiovascular DisordersMarket Size & Forecast (US$ billion), By Regions (2015 vs. 2020)

Figure 4. Global Prescription Pharmaceuticals for Cardiovascular Disorders MarketSize & Forecast (US$ billion), By Regions (2015 vs. 2020)


Asia is expected to be the fastest-growing regional segment of the prescription

pharmaceuticals for cardiovascular disorders market in the forecast period. This

market segment is estimated to grow at a CAGR of XX% from US$ XX billion in 2015

to US$ XX billion in 2020.

The prevalence of cardiovascular risk factors like high cholesterol, hypertension,

obesity, and diabetes have been on a rise in the rise in Asia, particularly Japan.

53.8

6

32.9

3

26.9

8

15.2

7

64.3

1

38.0

2

36.3

6

19.2

1

3.612.92

6.15

4.69


CAGR

% (2

015

–20

20)

Mar

ket S

ize (U

SD B

illio

n)

2015 2020 CAGR% (2015 – 2020)

SAMPLE

37

According to the American Heart Association, in Asia, around 21.0% have

hypertension, 3.7% have CHD, 6.1% have heart disease, and 1.9% has had a

stroke. According to WHO, over 80% of all deaths occur due to cardiovascular

disorders in developing countries.

4.2.3 Global Prescription Pharmaceuticals for Cardiovascular DisordersMarket Size & Forecast (US$ billion), By Regions (2013 – 2020)

Table 13. Global Prescription Pharmaceuticals for Cardiovascular Disorders MarketSize & Forecast (US$ billion), By Regions (2013 – 2020)

Regions 2013 2014 2015 2016 2017 2018 2019 2020 CAGR%(2015 –2020)

North America

Europe

Asia

RoW

Total


North America was the largest regional segment of the prescription pharmaceuticals

for cardiovascular disorders market in 2015. This market segment is estimated to

grow at a CAGR of XX% from US$ XX billion in 2015 to US$ XX billion in 2020.

Apart from a high prevalence of cardiac diseases, the soaring prices for prescription

drugs in North America also accounts for the large market size of prescription

pharmaceuticals.

4.2.4 North America Prescription Pharmaceuticals for CardiovascularDisorders Market Size & Forecast (US$ billion), By Country (2013 – 2020)

Table 14. North America Prescription Pharmaceuticals for Cardiovascular DisordersMarket Size & Forecast (US$ billion), By Country (2013 – 2020)

Country 2013 2014 2015 2016 2017 2018 2019 2020 CAGR%(2015 –2020)

U.S.

Canada

Total


SAMPLE

38

4.2.5 Europe Prescription Pharmaceuticals for Cardiovascular DisordersMarket Size & Forecast (US$ billion), By Country (2013 – 2020)

Table 15. Europe Prescription Pharmaceuticals for Cardiovascular DisordersMarket Size & Forecast (US$ billion), By Country (2013 – 2020)

Country 2013 2014 2015 2016 2017 2018 2019 2020 CAGR%(2015 –2020)

France

Germany

U.K.

Rest of Europe

Total


4.2.6 Asia Prescription Pharmaceuticals for Cardiovascular Disorders MarketSize (US$ Billion) & Forecast (US$ billion), By Country (2013 – 2020)

Table 16. Asia Prescription Pharmaceuticals for Cardiovascular Disorders MarketSize (US$ Billion) for Asia, By Country (2013 – 2020)

Country 2013 2014 2015 2016 2017 2018 2019 2020 CAGR%(2015 –2020)

China

Japan

India

Rest of Asia

Total


4.2.7 Rest of the World (RoW) Prescription Pharmaceuticals forCardiovascular Disorders Market Size & Forecast (US$ billion), ByCountry (2013 – 2020)

Table 17. Rest of the World (RoW) Prescription Pharmaceuticals for CardiovascularDisorders Market Size & Forecast (US$ billion), By Country (2013 – 2020)

Country 2013 2014 2015 2016 2017 2018 2019 2020 CAGR%(2015 –2020)

Latin America

Middle East and Africa

SAMPLE

39

Total


4.3 OncologyAccording to National Cancer Institute (U.S.), about 1.6 million new cases of cancer

will be diagnosed, and about 0.6 million people will die from the disease in the year

2016. According to a study carried out by the National Cancer Institute (U.S.)

between 2008 and 2012, the incidence of cancer cases was 454.8 per 100,000

people per year. Furthermore, the number of deaths due to cancer death was 171.2

per 100,000 individuals per year. Cancer mortality was observed to be higher among

men than women (207.9 per 100,000 men and 145.4 per 100,000 for women).

Approximately 39.6 % of men & women will be diagnosed with cancer at some point

during their lifetimes. The national expenditure on cancer in the U.S. was US$ 125

billion in 2010 and could reach US$ 156 billion by 2020.

4.3.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$billion), By Oncology (2013 – 2020)

Table 18. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion),By Oncology (2013 – 2020)

2013 2014 2015 2016 2017 2018 2019 2020 CAGR%(2015 –2020)




The global prescription pharmaceuticals for oncology market grew from US$ XX

billion in 2013 to US$ XX billion in 2015. This market is expected to grow at an

annual growth rate of between XX% and XX% in the forecast period. It is expected to

have a CAGR of XX% between 2015 and 2020.

SAMPLE

59

5 Prescription Pharmaceuticals Markets, by Formulations

5.1 IntroductionThe formulation segments of the prescription pharmaceuticals market included in this

report are capsules, tablets, inhalants and liquids, parenteral, and topicals.

Capsules were the largest formulation segment in 2015, and it is also expected to be

the fastest-growing formulation segment in the forecast period. The rise in the

geriatric population, the upsurge in the consumer preferences for capsules and

proliferation of pharmaceutical industries globally are factors responsible for the

growth of this formulation segment.

5.1.1 Global Prescription Pharmaceuticals Market Size & Forecast (US$billion), By Formulations (2015)

Figure 10. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion),By Formulations (2015)


Capsules, tablets, and inhalants and liquids were the three largest formulation

segments of the prescription pharmaceuticals market in 2015. The combined share

of these three formulation segments was XX% in 2015.

5.1.2 Global Prescription Pharmaceuticals Market Size & Forecast (US$billion), By Formulations (2013 – 2020)

Table 55. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion),By Formulations (2013 – 2020)

Formulations 2013 2014 2015 2016 2017 2018 2019 2020CAGR%(2015 –2020)

Capsules

USD726.89Billion

Capsules | USD 269.45 Billion

Tablets | USD 247.42 Billion

Inhalants and Liquids | USD 103.69 Billion

Parenterals | USD 71.34 Billion

Topicals | USD 34.99 BillionSAMPLE

60

Tablets


Parenterals

Topicals

Total


Capsules were the largest formulation segment of the prescription pharmaceuticals

market in 2015. This market segment is expected to grow at a CAGR of XX% from

US$ XX billion in 2015 to US$ XX billion in 2020.

Technological advancements are resulting in capsule dosing for dry powder inhalers,

vegetarian capsules or non-gelatin capsules, solid lipid pellet capsules and capsule-

in-capsule for sustained release effect, is expected to result in the growth of this

market.

5.2 CapsulesCapsules are solid dosage form and the drugs that are enclosed in a hard or soft

soluble container. The container is usually of a derivative of gelatine. This dosage

form is used by manufacturers when the drug cannot be compacted into a solid

tablet. Drugs administered in capsules forms are used for the treatment of

gastrointestinal diseases, neurological diseases, oncology, infectious diseases,

cardiovascular diseases, haematological diseases, and inflammatory diseases.

5.2.1 Global Capsules Market Size & Forecast (US$ billion) (2013 – 2020)Table 56. Global Capsules Market Size & Forecast (US$ billion) (2013 – 2020)

2013 2014 2015 2016 2017 2018 2019 2020 CAGR%(2015 –2020)




The global capsules market grew from US$ XX billion in 2013 to US$ XX billion in

2015. This market is expected to grow at an annual growth rate of between XX% and

XX% in the forecast period. It is expected to have a CAGR of XX% between 2015

and 2020.

SAMPLE

61

5.2.2 Global Capsules Market Size & Forecast (US$ billion), By Regions (2015vs. 2020)

Figure 11. Global Capsules Market Size & Forecast (US$ billion), By Regions (2015vs. 2020)


Asia is expected to be the fastest-growing regional segment of the capsules market

in the forecast period. This market segment is expected to grow at a CAGR of XX%

from US$ XX billion in 2015 to US$ XX billion in 2020. Owing to rise in health

awareness, affordability of healthcare services, and the growing number of

pharmaceutical industries, the Asia capsules market is expected to grow at a high

CAGR during the forecast period.

5.2.3 Global Capsules Market Size & Forecast (US$ billion), By Regions (2013– 2020)

Table 57. Global Capsules Market Size & Forecast (US$ billion), By Regions (2013 –2020)

Regions 2013 2014 2015 2016 2017 2018 2019 2020 CAGR%(2015 –2020)

North America

Europe

Asia

RoW

Total


103.

82

68.0

5

62.3

4

35.2

4

133.

71

84.6

1

90.2

8

47.5

7

5.194.45

7.69

6.18


CAGR

% (2

015

–20

20)

Mar

ket S

ize (U

SD B

illio

n)

2015 2020 CAGR% (2015 – 2020)

SAMPLE

69

6 Geographic Analysis

6.1 IntroductionThe regional segments of the prescription pharmaceuticals market included in this report are NorthAmerica, Europe, Asia, and Rest of the World (RoW). North America was the largest regionalsegment in 2015, while Asia is expected to be the fastest-growing regional segment in the forecastperiod.

6.1.1 Global Prescription Pharmaceuticals Market Size vs. CAGR% (2015 –2020), By Regions

Figure 16. Global Prescription Pharmaceuticals Market Size vs. CAGR% (2015 – 2020),By Regions


North America was the largest regional segments of the prescription

pharmaceuticals market in 2015. The market had a XX% share of the global market

in 2015.

6.1.2 Global Prescription Pharmaceuticals Market Size & Forecast (US$billion), By Regions (2013 – 2020)

Table 66. Global Prescription Pharmaceuticals Market Size & Forecast (US$ billion),By Regions (2013 – 2020)

Regions 2013 2014 2015 2016 2017 2018 2019 2020 CAGR%(2015 –2020)

North America

Europe

North America(2015)

Europe(2015)

Asia(2015)

RoW(2015) North America

(2020)

Europe(2020)

Asia(2020)

RoW(2020)

3

4

5

6

7

8

0 50 100 150 200 250 300 350 400

CAGR

% (2

015

–20

20)

Market Size (USD Billion)

SAMPLE

70

Asia

RoW

Total


North America was the largest regional segment of the prescription pharmaceuticals

market in 2015. This market segment is expected to increase at a CAGR of XX%

from US$ XX billion in 2015 to US$ XX billion in 2020.

6.2 North AmericaNorth America accounted for the largest share of the global prescription

pharmaceuticals market with US$ XX billion in 2015. Factors such as technological

advancements, rising incidences of chronic diseases, and positive government

initiatives are considered as the major driving factor for the growth of prescription

pharmaceuticals market in North America.

6.2.1 North America Prescription Pharmaceuticals Market Size & Forecast(US$ billion), By Country (2013 – 2020)

Table 67. North America Prescription Pharmaceuticals Market Size & Forecast (US$billion), By Country (2013 – 2020)

Country 2013 2014 2015 2016 2017 2018 2019 2020 CAGR%(2015 –2020)

U.S.

Canada

Total


6.2.2 North America Prescription Pharmaceuticals Market Size & Forecast(US$ billion), (2013 – 2020)

Table 68. North America Prescription Pharmaceuticals Market Size & Forecast (US$billion), (2013 – 2020)

2013 2014 2015 2016 2017 2018 2019 2020 CAGR%(2015 –2020)




SAMPLE

71

The prescription pharmaceuticals market in North America grew from US$ XX billion

in 2013 to US$ XX billion in 2015. This market is expected to grow at an annual

growth rate of between XX% and XX% in the forecast period. It is expected to have a

CAGR of XX% between 2015 and 2020.

Increased healthcare spending, expanding consumer access to health care owing to

the 2010 Patient Protection and Affordable Care Act (ACA), aging population, and

widespread rise of chronic diseases are fuelling the growth of prescription

pharmaceuticals in North America. The significant growth in biologics sales has also

boosted the prescription pharmaceuticals market. Also, North America possesses a

traditional stronghold of pharmaceutical innovation that is expected to augment this

market further.

6.2.3 North America Prescription Pharmaceuticals Market Size & Forecast(US$ billion), By Therapeutic Segments (2013 – 2020)

Table 69. North America Prescription Pharmaceuticals Market Size & Forecast (US$billion), By Therapeutic Segments (2013 – 2020)

Therapeutic Segments 2013 2014 2015 2016 2017 2018 2019 2020CAGR%(2015 –2020)


Oncology


Infectious Diseases

Metabolic Disorders


Other TherapeuticSegments

Total


Cardiovascular disorders were the largest therapeutic segment of the prescription

pharmaceuticals market in North America in 2015. This market segment is expected

to grow at a CAGR of XX% from US$ XX billion in 2015 to US$ XX billion in 2020.

SAMPLE

72

6.2.4 North America Prescription Pharmaceuticals Market Size & Forecast(US$ billion), By Formulations (2013 – 2020)

Table 70. North America Prescription Pharmaceuticals Market Size & Forecast (US$billion), By Formulations (2013 – 2020)

Formulations 2013 2014 2015 2016 2017 2018 2019 2020CAGR%(2015 –2020)

Capsules

Tablets


Parenterals

Topicals

Total


Capsules were the largest formulation segment of the prescription pharmaceuticals

market in North America in 2015. This market segment is expected to grow at a

CAGR of XX% from US$ XX billion in 2015 to US$ 133.71 billion in 2020.

SAMPLE

80

7 Competitive Landscape

7.1 Market Share AnalysisThe market share analysis studies the market share of the leading players operating in theprescription pharmaceuticals market. This market share analysis exclusively focused on prescriptionpharmaceuticals products and is estimated based on considering the global pharmaceutical productsmarket revenue for the year 2015. The value percentage for each company is based on the analysisof company’s investor presentations, annual reports, press releases, product offering particular toprescription pharmaceuticals segment and opinion of primary respondents. The below market sharediagram represents the revenue regarding value percentage for 2015 for each leading playersoperating in this market.

Figure 17. Market Share Analysis


7.2 Market Positioning of Key PlayersThe figure below represents the top-10 companies based on the criteria's: annual revenue,

combined total revenue of top-3 drug products, annual growth, and R&D investment.

Figure 18. Market Positioning of Key Players

4.1%5.2%5.0%

6.0%2.0%4.8%

3.8%

4.7%3.2%

3.0%

58.2%

Johnson & Johnson

Roche

Pfizer

Novartis AG

Bayer AG

Merck & Co., Inc.

GlaxoSmithKline Plc

Sanofi

Gilead Sciences

Astrazeneca

Others

SAMPLE

96

9 SCALAR 360 DEGREE MARKET REVIEWThe usage of prescription drugs over the years is set to increase across the globe. Nearly half of thisvolume growth is expected to occur in emerging markets, with India, China, Brazil and Indonesiadriving the spike in demand. In the developed markets, the volume of medicine use will remainstable. However, there will be an inclination towards the use of branded products as the use ofbiologics, or specialty medicines become more prevalent. The generic drugs, over the counter (OTC)products and imitative branded products, will fare better in the pharmerging markets and accountfor around 88% of total medicine use by 2020. The innovative specialty medicines have low adoptionrates in these countries.

Over the forecast period, a large number of innovative medicines is set to emerge from R&Dpipelines with products being focused on cancer, hepatitis C, autoimmune disorders, heart diseaseand some rare diseases. Owing to the presence of unparalleled treatment options, availability ofcheap drugs and increased use of evidence for decision making, stakeholders across the globe areset to obtain a higher return for their medicine investment than before.

The rapid development of technology will lead to changes in the treatment protocols, increase thepatient accountability and engagement, and accelerate the rate of adoption of behavioral changesthereby improving patient adherence to treatments. Patients suffering from multiple chronicdisorders can use wearables, mobile apps and other technologies to interact with providers andmanage their health.

The healthcare spending levels in developed markets will increase owing to branded drugs whereasgenerics will drive the spending levels in pharmerging markets. However, owing to the patentexpiries, around $150 billion would be saved on branded products, while over $30-40 billion wouldbe saved on biologics as biosimilars become widely adopted. Also, a large number of drugs focusedon chronic, rare or genetic diseases are expected to be launched thereby rendering significantclinical value.

Thus, the market is undergoing an evolution with traditional bigwigs, such as U.S and Europe,flipping over, and emerging markets giving rise to new potential markets. The healthcare investorsalso require rethinking a strategy by keeping an eagle eye on the emerging markets. They need tomake sure that they are not left behind owing to their low understanding of the true engines forgrowth.

10 Appendix

10.1 AcronymsTable 103. Acronyms

OTC Over the Counter

U.S. United States

GIP Global Innovative Pharma

GEP Global Established Pharma

VOC Vaccines, Oncology and Consumer Healthcare

R&D Research and Development

SAMPLE

97

U.K. United Kingdom

HCV Hepatitis C virus

HIV Human Immunodeficiency Virus

RoW Rest of the World

CAGR Compound annual growth rate

ACA Patient Protection and Affordable Care Act

COPD Chronic obstructive pulmonary disease

WHO World Health Organization

AARDAAmerican Autoimmune Related Diseases

Association

IMID Immune-mediated inflammatory diseases

SLE Systemic Lupus Erythematosus

RA Rheumatoid Arthritis

CHD Chronic Heart Disease

ASEAN Association of South-East Asian Nations

AEC ASEAN Economic Community

EMA European Medicines Agency

IDMP Identification of Medicinal Products

GVP Good Pharmacovigilance Practices

FDA Food and Drug Administration

GUDID Global Unique Device Identification DatabaseSAMPLE

Prescription pharmaceuticals market forecast to 2022 by scalar market research

Business

Transcript of Prescription pharmaceuticals market forecast to 2022 by scalar market research